Cellectis bioresearch and Syngene announce partnership on the development of customized cell lines

Cellectis bioresearch, the specialist in Genome customization and commercial subsidiary of Cellectis (Alternext: ALCLS), and Syngene International Ltd, an internationally reputed contract research and manufacturing services (CRAMS) organization and subsidiary of BIOCON Ltd, India’s largest Biotechnology company by revenue, announced today that they have entered into an agreement to develop novel genetically customized cell lines.
 

This partnership between Cellectis bioresearch and Syngene will leverage Cellectis’ patented technology in Genome customization with Syngene’s strong biology platform and capabilities to develop novel recombinant and Knock-out cell lines for use in oncology- and ADME-Tox-based drug discovery studies.
 

“This new partnership with Syngene International will enable us to mobilize each organization‘s expertise and know-how and create synergies that will deliver hundreds of engineered cell lines for drug discovery and functional genomics” said Marc Le Bozec, Chief Executive Officer, Cellectis bioresearch.
 

Peter Bains, Chief Operating Officer, Syngene International said, “We are very pleased to enter into this strategic collaboration with Cellectis bioresearch. This is a very exciting R&D arena, employing state-of-the-art technologies, and we are delighted to have the opportunity to support Cellectis’ goals through our biology platform at Syngene.’’